IMMUNITYBIO INC (IBRX)

Investors Bag IBRX 6.2% Lower Than Its Secondary Stock Offering

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Noteworthy Wednesday Option Activity: PIPR, CRK, IBRX

Wednesday's session: top gainers and losers

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Which stocks are experiencing notable movement on Wednesday?

Which stocks are experiencing notable movement on Wednesday?

The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Gap analysis on 2024-12-11: gap up and gap down stocks in today's session.

Top movers in Wednesday's pre-market session

Top movers in Wednesday's pre-market session

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

Which stocks are moving after the closing bell on Tuesday?

As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move

Biotech billionaire Patrick Soon-Shiong was accused in a shareholder lawsuit of misleading ImmunityBio Inc. investors about the prospects of the company’s flagship cancer drug in order to enrich himself at their expense.

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

/PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform...

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

/PRNewswire/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the...

ImmunityBio Reports Third-Quarter 2024 Financial Results

Commit To Buy ImmunityBio At $4, Earn 25% Using Options

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Notable Friday Option Activity: IBRX, EVLV, CRI

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Notable Monday Option Activity: ROKU, FLR, IBRX

Noteworthy Friday Option Activity: TGT, IBRX, UDMY

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

Noteworthy Monday Option Activity: IBRX, TGTX, NTNX